300 related articles for article (PubMed ID: 23274891)
1. Mutations in HNF1A result in marked alterations of plasma glycan profile.
Thanabalasingham G; Huffman JE; Kattla JJ; Novokmet M; Rudan I; Gloyn AL; Hayward C; Adamczyk B; Reynolds RM; Muzinic A; Hassanali N; Pucic M; Bennett AJ; Essafi A; Polasek O; Mughal SA; Redzic I; Primorac D; Zgaga L; Kolcic I; Hansen T; Gasperikova D; Tjora E; Strachan MW; Nielsen T; Stanik J; Klimes I; Pedersen OB; Njølstad PR; Wild SH; Gyllensten U; Gornik O; Wilson JF; Hastie ND; Campbell H; McCarthy MI; Rudd PM; Owen KR; Lauc G; Wright AF
Diabetes; 2013 Apr; 62(4):1329-37. PubMed ID: 23274891
[TBL] [Abstract][Full Text] [Related]
2. Interlaboratory evaluation of plasma N-glycan antennary fucosylation as a clinical biomarker for HNF1A-MODY using liquid chromatography methods.
Demus D; Jansen BC; Gardner RA; Urbanowicz PA; Wu H; Štambuk T; Juszczak A; Medvidović EP; Juge N; Gornik O; Owen KR; Spencer DIR
Glycoconj J; 2021 Jun; 38(3):375-386. PubMed ID: 33765222
[TBL] [Abstract][Full Text] [Related]
3. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.
Besser RE; Shepherd MH; McDonald TJ; Shields BM; Knight BA; Ellard S; Hattersley AT
Diabetes Care; 2011 Feb; 34(2):286-91. PubMed ID: 21270186
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein M can discriminate HNF1A-MODY from Type 1 diabetes.
Mughal SA; Park R; Nowak N; Gloyn AL; Karpe F; Matile H; Malecki MT; McCarthy MI; Stoffel M; Owen KR
Diabet Med; 2013 Feb; 30(2):246-50. PubMed ID: 23157689
[TBL] [Abstract][Full Text] [Related]
5. Plasma Fucosylated Glycans and C-Reactive Protein as Biomarkers of HNF1A-MODY in Young Adult-Onset Nonautoimmune Diabetes.
Juszczak A; Pavić T; Vučković F; Bennett AJ; Shah N; Pape Medvidović E; Groves CJ; Šekerija M; Chandler K; Burrows C; Rojnić Putarek N; Vučić Lovrenčić M; Ćuća Knežević J; James TJ; Gloyn AL; Lauc G; McCarthy MI; Owen KR; Gornik O
Diabetes Care; 2019 Jan; 42(1):17-26. PubMed ID: 30455330
[TBL] [Abstract][Full Text] [Related]
6. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations.
Owen KR; Thanabalasingham G; James TJ; Karpe F; Farmer AJ; McCarthy MI; Gloyn AL
Diabetes Care; 2010 Sep; 33(9):1919-24. PubMed ID: 20724646
[TBL] [Abstract][Full Text] [Related]
7. Intima-media thickness and endothelial dysfunction in GCK and HNF1A-MODY patients.
Szopa M; Osmenda G; Wilk G; Matejko B; Skupien J; Zapala B; Młynarski W; Guzik T; Malecki MT
Eur J Endocrinol; 2015 Mar; 172(3):277-83. PubMed ID: 25501962
[TBL] [Abstract][Full Text] [Related]
8. A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes.
Thanabalasingham G; Shah N; Vaxillaire M; Hansen T; Tuomi T; Gašperíková D; Szopa M; Tjora E; James TJ; Kokko P; Loiseleur F; Andersson E; Gaget S; Isomaa B; Nowak N; Raeder H; Stanik J; Njolstad PR; Malecki MT; Klimes I; Groop L; Pedersen O; Froguel P; McCarthy MI; Gloyn AL; Owen KR
Diabetologia; 2011 Nov; 54(11):2801-10. PubMed ID: 21814873
[TBL] [Abstract][Full Text] [Related]
9. A decision algorithm to identify patients with high probability of monogenic diabetes due to HNF1A mutations.
Szopa M; Klupa T; Kapusta M; Matejko B; Ucieklak D; Glodzik W; Zapala B; Sani CM; Hohendorff J; Malecki MT; Skupien J
Endocrine; 2019 Apr; 64(1):75-81. PubMed ID: 30778899
[TBL] [Abstract][Full Text] [Related]
10. HNF1A gene p.I27L is associated with early-onset, maturity-onset diabetes of the young-like diabetes in Turkey.
Beysel S; Eyerci N; Pinarli FA; Kizilgul M; Ozcelik O; Caliskan M; Cakal E
BMC Endocr Disord; 2019 May; 19(1):51. PubMed ID: 31109344
[TBL] [Abstract][Full Text] [Related]
11. Effects of hepatocyte nuclear factor-1A and -4A on pancreatic stone protein/regenerating protein and C-reactive protein gene expression: implications for maturity-onset diabetes of the young.
Kyithar MP; Bonner C; Bacon S; Kilbride SM; Schmid J; Graf R; Prehn JH; Byrne MM
J Transl Med; 2013 Jun; 11():156. PubMed ID: 23803251
[TBL] [Abstract][Full Text] [Related]
12. Fucosylated AGP glycopeptides as biomarkers of HNF1A-Maturity onset diabetes of the young.
Tijardović M; Štambuk T; Juszczak A; Keser T; Gasperikova D; Novokmet M; Tjora E; Pape Medvidović E; Stanik J; Rasmus Njølstad P; Lauc G; Owen KR; Gornik O
Diabetes Res Clin Pract; 2022 Mar; 185():109226. PubMed ID: 35122907
[TBL] [Abstract][Full Text] [Related]
13. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
McDonald TJ; Shields BM; Lawry J; Owen KR; Gloyn AL; Ellard S; Hattersley AT
Diabetes Care; 2011 Aug; 34(8):1860-2. PubMed ID: 21700917
[TBL] [Abstract][Full Text] [Related]
14. Maturity Onset Diabetes of the Young (MODY) in Tunisia: Low frequencies of GCK and HNF1A mutations.
Ben Khelifa S; Martinez R; Dandana A; Khochtali I; Ferchichi S; Castaño L
Gene; 2018 Apr; 651():44-48. PubMed ID: 29408271
[TBL] [Abstract][Full Text] [Related]
15. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young.
Thanabalasingham G; Pal A; Selwood MP; Dudley C; Fisher K; Bingley PJ; Ellard S; Farmer AJ; McCarthy MI; Owen KR
Diabetes Care; 2012 Jun; 35(6):1206-12. PubMed ID: 22432108
[TBL] [Abstract][Full Text] [Related]
16. Circulating ghrelin level is higher in HNF1A-MODY and GCK-MODY than in polygenic forms of diabetes mellitus.
Nowak N; Hohendorff J; Solecka I; Szopa M; Skupien J; Kiec-Wilk B; Mlynarski W; Malecki MT
Endocrine; 2015 Dec; 50(3):643-9. PubMed ID: 25987348
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.
Pal A; Farmer AJ; Dudley C; Selwood MP; Barrow BA; Klyne R; Grew JP; McCarthy MI; Gloyn AL; Owen KR
Diabetes Care; 2010 Feb; 33(2):252-7. PubMed ID: 19933992
[TBL] [Abstract][Full Text] [Related]
18. Identification of HNF1A-MODY and HNF4A-MODY in Irish families: phenotypic characteristics and therapeutic implications.
Kyithar MP; Bacon S; Pannu KK; Rizvi SR; Colclough K; Ellard S; Byrne MM
Diabetes Metab; 2011 Dec; 37(6):512-9. PubMed ID: 21683639
[TBL] [Abstract][Full Text] [Related]
19. Development of an exoglycosidase plate-based assay for detecting α1-3,4 fucosylation biomarker in individuals with HNF1A-MODY.
Demus D; Urbanowicz PA; Gardner RA; Wu H; Juszczak A; Štambuk T; Medvidović EP; Owen KR; Gornik O; Juge N; Spencer DIR
Glycobiology; 2022 Mar; 32(3):230-238. PubMed ID: 34939081
[TBL] [Abstract][Full Text] [Related]
20. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
Hohendorff J; Szopa M; Skupien J; Kapusta M; Zapala B; Platek T; Mrozinska S; Parpan T; Glodzik W; Ludwig-Galezowska A; Kiec-Wilk B; Klupa T; Malecki MT
Endocrine; 2017 Aug; 57(2):272-279. PubMed ID: 28593615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
